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Abstract
Background: There is little knowledge regarding the prevalence and nature of renal impairment
in African populations initiating antiretroviral treatment, nor evidence to inform the most cost
effective methods of screening for renal impairment. With the increasing availability of the
potentially nephrotixic drug, tenofovir, such information is important for the planning of
antiretroviral programmes
Methods: (i) Retrospective review of the prevalence and risk factors for impaired renal function
in 2189 individuals initiating antiretroviral treatment in a rural African setting between 2004 and
2007 (ii) A prospective study of 149 consecutive patients initiating antiretrovirals to assess the
utility of urine analysis for the detection of impaired renal function. Severe renal and moderately
impaired renal function were defined as an estimated GFR of ≤ 30 mls/min/1.73 m2 and 30–60 mls/
min/1.73 m2 respectively. Logistic regression was used to determine odds ratio (OR) of significantly
impaired renal function (combining severe and moderate impairment). Co-variates for analysis
were age, sex and CD4 count at initiation.
Results: (i) There was a low prevalence of severe renal impairment (29/2189, 1.3% 95% C.I. 0.8–
1.8) whereas moderate renal impairment was more frequent (287/2189, 13.1% 95% C.I. 11.6–14.5)
with many patients having advanced immunosuppression at treatment initiation (median CD4 120
cells/μl). In multivariable logistic regression age over 40 (aOR 4.65, 95% C.I. 3.54–6.1), male gender
(aOR 1.89, 95% C.I. 1.39–2.56) and CD4<100 cells/ul (aOR 1.4, 95% C.I. 1.07–1.82) were
associated with risk of significant renal impairment (ii) In 149 consecutive patients, urine analysis
had poor sensitivity and specificity for detecting impaired renal function.
Conclusion: In this rural African setting, significant renal impairment is uncommon in patients
initiating antiretrovirals. Urine analysis alone may be inadequate for identification of those with
impaired renal function where resources for biochemistry are limited.
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Background
Renal disease is an important complication of both HIV
infection [1] and antiretroviral treatment [2]. In a Western
setting HIV-related renal disease appears to be more com-
mon in populations of African descent [3,4] and as
antiretroviral roll-out continues across sub-Saharan
Africa, the prevalence and nature of renal impairment in
HIV positive individuals from African populations is of
increasing importance [5]. However, little data exists on
the prevalence of renal impairment before or during
antiretroviral treatment in rural African areas, and in par-
ticular there is very little data from non-specialist centres
or research programmes.
Such information is important for individual patient care,
the programmatic choice of antiretrovirals and strategies
for monitoring toxicity. In most roll-out programmes in
Sub-Saharan Africa, stavudine and lamivudine are first
line medications and should have their dosages reduced
in the setting of renal impairment; without doing so the
chance of toxicity may be increased [6]. Similarly, patients
with pre-existing renal disease are likely to require closer
monitoring once treatment is initiated.
With an ongoing discussion about the possibility of intro-
ducing tenofovir as first line treatment in countries such as
South Africa (which is home to approximately one in six
of the world's HIV positive population[7]), following it's
recommendation by WHO [8], the prevalence of renal
impairment takes on additional importance as patients
with pre-existing renal impairment might either require
alternative treatments or be at greater risk of toxicity and
require more intensive monitoring [9].
In many resource-poor settings within Sub-Saharan
Africa, the diagnosis of renal impairment using blood bio-
chemistry is not a routine matter. Point of care tests, par-
ticularly urine analysis, offer a possible method of
screening patients at risk of renal disease with the poten-
tial for targeting high risk groups for more intensive mon-
itoring.
We set out to establish the prevalence of, and risk factors
for, renal impairment in a large rural South African
antiretroviral programme and, in addition, to study
whether the presence of renal impairment could be pre-
dicted by urine analysis.
Methods
Patients were recruited from a public sector service in the
rural Hlabisa sub-district of KwaZulu Natal, South Africa.
The local antiretroviral programme began in late 2004 as
a partnership between the Department of Health and the
Africa Centre for Health and Population Studies, Som-
khele. The service is run according to South African
National guidelines and thus patients become eligible for
treatment on the basis of a CD4 count below 200 cells/ml
or WHO Stage IV disease. Prior to initiation with stavu-
dine, lamivudine and either efavirenz or nevirapine,
patients routinely have baseline blood biochemistry per-
formed, including serum creatinine.
Details of age, sex, weight, CD4 count, and serum creati-
nine were collected where available from medical records
from all 2500 patients initiating treatment between
November 2004 and June 2007. Patients who had previ-
ously received combination antiretrovirals and patients
under the age of 16 years were excluded.
GFR was estimated (eGFR) with the widely-used, abbrevi-
ated four variable MDRD method [2]. All patients were of
Zulu ethnicity and thus for the MDRD calculation of the
prevalence of renal impairment, the ethnicity correction
factor of 1.21 was excluded on the assumption that the
population would not differ from the population of black
South Africans for whom this method was recently vali-
dated in a hospitalised population [10]. Cockcroft-Gault
estimations were not performed as height measurements,
required to calculate BSA, were not available for the
majority of individuals studied.
Severe renal impairment was defined as an estimated GFR
(eGFR) <30 mls/min/1.73 m2, moderate renal impair-
ment as an eGFR of 30–60 mls/min/1.73 m2 and mild
renal impairment as an eGFR 60–90 mls/min/1.73 m2.
Significant renal impairment was defined as the combina-
tion of these two (i.e. those with eGFR less than or equal
to 60 mls/min/1.73 m2) as this population might require
dose alteration to antiretroviral treatments.
Risk factors for renal impairment were estimated with
logistic regression using the Stata10 package (StataCorp,
Texas). Significant renal impairment (defined above) was
the outcome variable. Demographic variables were
included in the model, along with CD4 count at initiation
(available for 1909 individuals).
In a separate analysis more detailed clinical data were
recorded for 149 consecutive individuals initiating treat-
ment. In addition to baseline demographics, single read-
ings of blood pressure, random capillary glucose and
urinalysis were made. One individuals was excluded from
analysis as recorded to be menstruating. Urine analysis
was performed using Multistix™ (Bayer, Germany) record-
ing significant proteinuria (≥ 1+) and haematuria (≥ 1+).
Individual informed consent was obtained from all partic-
ipants in the programme to allow use of anonymised rou-
tine clinical data in research. Ethical approval was
obtained from the ethics committee of University of Kwa-
Zulu Natal and the research office of KwaZulu Natal
Department of Health.
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Results
i) Prevalence and risk factors for renal impairment
192 individuals were either aged under 16 or had previ-
ously received combination antiretrovirals and were
excluded. 119 had no record of baseline creatinine availa-
ble and were excluded, leaving 2189 individuals for anal-
ysis.
1505 individuals were female (68.8%) and 684 (31.2%)
male. Other baseline characteristics are shown in Table 1.
Estimates of the proportion of patients with severe, mod-
erate, mild reductions in eGFR (as defined above) are in
Table 2. Within the most severe category, 8/29 had eGFR
of less than 15 mls/min/1.73 m2 and 21/29 15–30 mls/
min/1.73 m2. If the ethnicity factor of 1.21 had been
applied the numbers of patients with categorised with
renal impairment were 18/2189 (0.8%) with eGFR<30
mls/min/1.73 m2, 110/2189 (5.0%) with eGFR 30–60
mls/min/1.73 m2.
For logistic regression, significant renal impairment
(defined above) was used as the outcome variable.
Dependent variables were age, gender and CD4 count.
Univariably, male gender was significantly associated
with outcome (OR 1.57, 95% CI 1.19–2.08 P < 0.01). Age
and CD4 count were also associated with outcome both as
continuous variables; age (OR 1.08 95% CI 1.07–1.09, P
< 0.01), CD4 count (OR 0.99 CI 0.996–0.999, P = 0.041)
and when coded as categorical values with age over 40
(OR 4.21, 95% CI 3.27–5.42 P < 0.01) or CD4 count <100
(OR 1.16 95% CI 0.90–1.49 P = 0.21). Categorical varia-
bles only were taken forward for the multivariable analy-
sis the results, results are shown in Table 3.
ii) Sensitivity and specificity of urine analysis
In the consecutive series of 149 patients initiating antiret-
roviral therapy, the prevalence of renal impairment was
similar to the larger cohort with 3/149 (2%) classified as
severe renal impairment and 19/149 (12.9%) having
moderate renal impairment. One patient had a blood
pressure single reading with diastolic >90 mmHg and one
patient had a random glucose of >11.1 but neither had
significant renal impairment. 25/149 (16.7%) of individ-
uals had evidence of haematuria, 39/149 (26.1%) had
evidence of proteinuria, 53/149 (35.6%) had evidence of
either proteinuria or haematuria and 63/149 (42.2%) had
evidence of renal dysfunction (defined as either reduced
eGFR and/or proteinuria/haematuria). Of those with pro-
teinuria, 16/39 were recorded with 1+ protein, 18/39 with
2+ protein and 5/39 with 3+ protein.
The sensitivity of significant blood and protein on urine
dipstix was assessed in a field setting. 6/22 (27.2%)
patients with significant renal impairment had detectable
protein and 7/22 (31.8%) detectable blood in their urine.
12/22 (54.5%) had either significant blood or protein.
33/127 (25.9%) of those without significant renal impair-
ment had significant proteinuria whilst 18/127 (14.1%)
had significant haematuria. Either significant proteinuria
or haematuria was seen in 12/22 (54.5%) individuals
with significant renal impairment and 41/127 (32.2%)
without. Sensitivity, Specificty and positive predictive val-
ues for either the presence of blood, presence of protein or
presence of either are shown in table 4.
Discussion
Over the coming years most people initiating antiretroviral
treatment will do so in resource poor environments where
laboratory investigations are limited and, in particular, in
sub-Saharan Africa. Real world data from such settings is
therefore important in prioritising the use of scarce resources
for planning diagnostic, therapeutic and monitoring
options. The data presented here represent the first pub-
lished study to date of renal impairment from a rural African
antiretroviral programme. There are reasons to think that
impaired renal function might be common in such settings
as African ethnicity and advanced immunosuppression
[3,11] are identified risk factors for renal disease in a devel-
oped world setting. In this study we find severe renal impair-
ment to be uncommon, even in a population starting
treatment late in disease progression. Moderate renal impair-
ment was more common with a prevalence of 14.4%.
The prevalence of significant renal impairment described
here is slightly higher than seen in a recently reported Ken-
Table 1: Baseline characteristics of initiating cohort studied
Median IQR (25–75)
Age (yrs) 36 30–43
Weight (kg) 59 52.1–67.5
Height (cm) 161 156–167
CD4 (cells/ul) 119 59–175
Table 2: GFR estimated by abbreviated MDRD methods 
(without ethnicity correction)
N % 95% CI
0–29 29 1.3 0.8–1.8
30–59 287 13.1 11.6–14.5
60–89 1250 57.1 55.0–59.2
90 or more 623 28.4 26.6–30.3
2189
Table 3: Multivariable logistic regression
aOR1 P 95% C.I.
Age over 40 4.65 <0.01 3.54 – 6.10
Male 1.89 <0.01 1.39 – 2.56
CD4 <100 1.40 0.02 1.07 – 1.82
1Adjusted for other variables in the table
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yan cohort of untreated patients who had a significantly
higher CD4 counts [12]. However, the prevalence is lower
than in a Ugandan study of home based care where more
severe cases of renal disease had already been excluded
[13] and where a similar association with increasing age
was also observed. Direct comparisons have to be tem-
pered by an understanding that there are significant differ-
ences in the populations studied. Additionally, whilst the
best validated method for estimating eGFR in this popula-
tion was used without a correction for ethnicity, this
method has not been validated in other African popula-
tions for which it might be appropriate.
Of note, mildly impaired renal function was common.
The terminology used here is not meant to imply that this
is not significant. However, although common, such
patients are unlikely to need changes to doses of medica-
tion or additional monitoring. Furthermore, moderate or
mild renal impairment might well improve on antiretro-
viral therapy [14] and its relevance to programmatic deci-
sions on drug choice and monitoring is therefore not
clear.
These findings are likely to be representative of many
patients starting treatment outside of specialist centres in
rural Africa. A small number of individuals were excluded
due to missing values of creatinine but there is no reason
to think that these individuals were sicker or more likely
to have different creatinine levels from others included.
Although there is little data for comparison, the relatively
low prevalence of severe renal impairment seen here
could reflect the fact that the local service is provided
through a network of rural primary healthcare facilities
reducing potential biases seen when collecting data from
large centres, clinical trials or well organised urban
cohorts which might recruit sicker or more complex
patients.
Another possible explanation is that South African guide-
lines create a relatively high barrier to accessing antiretro-
viral treatment. Dedicated HIV services are often separate
from hospital wards where many patients receive their
first diagnosis and patients are required to undergo a
period of education and training before treatment is
started. Combined, these features might make it harder
for sicker patients to start antiretrovirals. However,
approximately one in seven HIV positive individuals in
the world are living in South Africa and many, both in
South Africa and beyond, are living in rural areas which
means this data is likely to be representative of many pop-
ulations starting antiretrovirals in Africa.
Other possible factors including circulating viral subtype,
the prevalence of opportunistic infection and differences
in human genetic structure, could also all contribute to
differences in the prevalence of renal disease between Afri-
can populations. It is interesting to note that in the recent
study validating the MDRD estimation in South African
blacks [10], the correction applied for African-Americans
was not required, suggesting a differing genetic back-
ground with regard to renal disease between populations
originating from Southern Africa and those from West
Africa.
Nonetheless, information on the prevalence of conditions
such as renal disease is valuable for the planning of
antiretroviral services, particularly when there is a discus-
sion about introducing tenofovir and where there are
financial limitations for costs of both treatment and mon-
itoring.
The costs of monitoring to prevent and detect toxicity
from antiretrovirals depend not only on the prevalence of
renal impairment but also whether costs can be reduced
by inexpensive identification of a sub-group of patients
who could be targeted for more intensive monitoring. It
appears that in this setting, the use of routine simple uri-
nalysis is not helpful in identifying an "at-risk" popula-
tion.
Given the relatively small sample size for the assessment
of urine analysis, these results need to be interpreted with
caution. However, given what is known of the causes of
renal diseases in the populations of Southern Africa, it is
perhaps surprising that proteinuria in particular is not a
more useful screening test.
Renal biopsy is not routinely available outside of a few
specialist centres in South Africa and thus the causes of
renal disease in this study cannot be stated with confi-
dence. In a facility based series from Johannesburg, the
Table 4: Sensitivity and specificity of urine analysis for detecting significantly impaired renal function
Presence blood Presence Protein Presence either blood or protein
Sensitivity 0.31 (0.15–0.55) 0.27 (0.11–0.50) 0.55 (0.32–0.75)
Specificity 0.85 (0.78–0.91) 0.74 (0.65–0.81) 0.68 (0.59–0.76)
PPV 0.28 (0.13–0.49) 0.15 (0.06–0.31) 0.22 (0.13–0.19)
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aetiology of renal disease in HIV positive and HIV nega-
tive individuals differed significantly with HIV nephropa-
thy (HIVAN), and HIV Immune Complex Kidney diseases
(HIVICK) diagnosed in nearly half of all biopsies from
HIV positive patients between 2003 and 2004[15]. These
conditions are typically associated with proteinuria [16]
as are the more common diseases of hypertension and
diabetes, for which little other evidence was found in this
population starting antiretrovirals despite a high preva-
lence locally[17]. There are different possible interpreta-
tions for this finding. One possibility is that intercurrent
illness and acute tubular necrosis might be a more com-
mon aetiology in this population and most patients are
symptomatic by the time they present for treatment. How-
ever, this conclusion cannot be sustained from the data
here. Recently published data also suggests another possi-
ble explanation for the low levels of proteinuria detected.
In a study from the US (with 94% African-American par-
ticipants) urine dipsticks were found to be poorly sensi-
tive to significant proteinuria detected by raised urine
protein-creatinine ratios in HIV positive patients[18].
Conclusion
Regardless of the underlying pathology these data do sug-
gest that low cost tests such as urine analysis might not be
sufficiently sensitive to be used as a single screening test
for renal disease at baseline and there might not be an
easy alternative to blood or urine biochemistry for screen-
ing patients initiating antiretrovirals in rural African pop-
ulations. Further work will be needed to establish cost-
effective means of identifying the small proportion of
individuals with severe renal impairment, and larger stud-
ies to investigate this are required.
The extent to which this data is representative of the pop-
ulation at need of treatment in Southern Africa cannot be
stated confidently, however, it is likely to represent a less
biased population than many other sources. The data do
suggest that renal impairment might not be as common as
sometimes feared and that, in itself, it should not be seen
as an impediment changes in the first line medication
delivered through public health programmes in sub-Saha-
ran Africa.
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